Department of Ophthalmology, National Taiwan University Hospital, Taipei.
Eye (Lond). 2009 Feb;23(2):397-406. doi: 10.1038/sj.eye.6703017. Epub 2007 Nov 2.
To compare the anatomic and functional outcomes of treating thick submacular haemorrhage with intravitreal gas injection with and without tissue plasminogen activator (t-PA) in patients with age-related macular degeneration.
A review of age-related macular degeneration patients with submacular haemorrhage who underwent intravitreal gas injection with and without t-PA at a tertiary referral centre was conducted. Main outcome measures were best and final postoperative visual acuity.
A total of 53 eyes of 53 patients were included, 28 eyes received intravitreal t-PA and gas injection (t-PA and gas group) and 25 eyes received intravitreal gas injection alone (gas-alone group). Incidence of best visual acuity improvement was significantly higher in the t-PA and gas group than in the gas-alone group (60.7 vs 32.0%; P=0.037). However, subgroup analysis demonstrated that the difference was significant only in eyes with haemorrhage duration of more than 14 days (46.2 vs 8.3%; P=0.035). Incidence of final visual acuity improvement was not significantly different between the two groups (42.9 vs 28.0%; P=0.39). The complications of vitreous haemorrhage and endophthalmitis were similar between the two groups. Multiple logistic regression analysis demonstrated that shorter haemorrhage duration (<14 days) was the main factor predictive of best visual acuity improvement (OR=9.02, P=0.015). Whether t-PA was used was of borderline significance (OR=4.96, P=0.046).
Intravitreal t-PA was valuable for submacular haemorrhage only in eyes with relatively old haemorrhage. For eyes with recent onset of emorrhage, t-PA is suggested only if initial gas injection failed to displace submacular haemorrhage.
比较伴有和不伴有组织型纤溶酶原激活剂(t-PA)的玻璃体内气体注射治疗年龄相关性黄斑变性伴黄斑下厚出血的解剖和功能结果。
对在三级转诊中心接受伴有和不伴有 t-PA 的玻璃体内气体注射治疗的年龄相关性黄斑变性伴黄斑下出血的患者进行回顾性研究。主要观察指标为最佳和最终术后视力。
共纳入 53 例 53 只眼患者,28 只眼接受玻璃体内 t-PA 和气体注射(t-PA 和气体组),25 只眼仅接受玻璃体内气体注射(气体组)。t-PA 和气体组最佳视力改善的发生率明显高于气体组(60.7%比 32.0%;P=0.037)。然而,亚组分析表明,这种差异仅在出血时间超过 14 天的眼(46.2%比 8.3%;P=0.035)中显著。两组最终视力改善的发生率无显著差异(42.9%比 28.0%;P=0.39)。两组玻璃体积血和眼内炎的并发症相似。多因素逻辑回归分析表明,出血时间较短(<14 天)是最佳视力改善的主要预测因素(OR=9.02,P=0.015)。是否使用 t-PA 具有边缘意义(OR=4.96,P=0.046)。
玻璃体内 t-PA 仅对相对陈旧性出血的眼黄斑下出血有价值。对于新近发生出血的眼,如果初始气体注射未能使黄斑下出血移位,则建议使用 t-PA。